Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Reactivation of dormant breast cancer cells at metastatic sites may require these cells to overcome organ-specific suppressive signals in the microenvironment and to activate stem cell-like traits.
Two papers report that combined inhibition of PI3K and poly(ADP) ribose polymerase (PARP) is synergistic in BRCA1-defective and BRCA-proficient triple-negative breast cancer.
Unlicensed natural killer cells are important in the response of patients with high risk neuroblastoma to treatment with GD2-specific monoclonal antibodies.
Two papers published inCancer Celldescribe molecular pathways involved in blood vessel normalization, and support the idea that a normalized vasculature can enhance the efficacy of chemotherapy and radiotherapy.
Chromothripsis is an emerging phenomenon that results in chromosome rearrangements in tumour cells. This Review discusses the possible mechanisms underlying this process and its implications for cancer biology and in the clinic.
Treating cancer patients with T cell-based therapies has shown some some promise in the clinic, but not all patients respond. There could be many reasons for this, some of which might be addressed by using the best possible antitumour T cell. What are the biological properties of such a cell and can we generate one?
What have mitochondria ever done for us? This Review discusses why alterations in cellular processes that require mitochondria are essential for tumorigenesis.
As part of our Series of articles on The next 10 years in cancer research, this Opinion article discusses what the future may hold for angiogenesis inhibitors as cancer therapeutics.
Chromatin conformation and chromatin modifications affect DNA damage response signalling and hence the associated cellular outcomes of this response. This Opinion article discusses the implications of chromatin alterations in cancer cells on DNA damage responses.
Individuals with Down's syndrome have an increased risk of developing leukaemia in childhood, but they also have a significantly reduced risk of developing most solid tumours. However, Down's syndrome shares many features with cancer-prone syndromes, so why is Down's syndrome different?
